Leuprorelin - Generex Biotechnology Corporation/NHTherapeuticsAlternative Names: NH 901
Latest Information Update: 29 May 2015
At a glance
- Originator Generex Biotechnology Corporation; NHTherapeutics
- Developer Generex Biotechnology Corporation
- Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
- Mechanism of Action Gonadotropin releasing hormone stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hypogonadism